Solubility Measurement and Mathematical Modeling for Bosentan in Mixtures of Ethylene Glycol and Water at 293.15-313.15 K

被引:12
作者
Moradi, Milad [1 ,2 ,3 ]
Rahimpour, Elaheh [1 ,2 ,4 ]
Jafari, Parisa [1 ,2 ,5 ]
Jouyban, Abolghasem [1 ,2 ,6 ]
机构
[1] Tabriz Univ Med Sci, Pharmaceut Anal Res Ctr, Tabriz 5165665811, Iran
[2] Tabriz Univ Med Sci, Fac Pharm, Tabriz 5165665811, Iran
[3] Tabriz Univ Med Sci, Student Res Comm, Fac Pharm, Tabriz, Iran
[4] Tabriz Univ Med Sci, Food & Drug Safety Res Ctr, Tabriz, Iran
[5] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran
[6] Near East Univ, Fac Pharm, Mersin 10,POB 99138, Nicosia, North Cyprus, Turkey
关键词
Bosentan; Ethylene glycol; Cosolvent mixtures; Cosolvency models; Solubility prediction; SOLVENT MIXTURES; ETHANOL;
D O I
10.1007/s10953-022-01227-2
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
The molar solubility of bosentan (BST) in mixtures of ethylene glycol (EG) + water at different temperatures from 293.15 to 313.15 K was measured by using the shake flask technique. Experimental solubility increased with increasing temperature and mass fraction of cosolvent; so that, the largest solubility was found in neat cosolvent at 313.15 K. The cosolvency models of Jouyban-Acree and its combined version with van't Hoff equation (Jouyban-Acree-van't Hoff model) were used for correlation of BST solubility data with the low values of mean relative deviations (MRD% <= 8.1). Furthermore, some untested data were predicted based on the achieved trained models at 298.15 K. X-ray powder diffraction was also served to analyze the equilibrium solid phase crystal of BST and the results turns out that no polymorphic transformation, solvate formation or crystal transition during the whole solvent crystallization process.
引用
收藏
页码:218 / 227
页数:10
相关论文
共 32 条
  • [21] Solvent selection for pharmaceuticals
    Kolár, P
    Shen, JW
    Tsuboi, A
    Ishikawa, T
    [J]. FLUID PHASE EQUILIBRIA, 2002, 194 : 771 - 782
  • [22] Physicochemical Properties of Bosentan and Selected PDE-5 Inhibitors in the Design of Drugs for Rare Diseases
    Krupa, Anna
    Majda, Dorota
    Mozgawa, Wlodzimierz
    Szlek, Jakub
    Jachowicz, Renata
    [J]. AAPS PHARMSCITECH, 2017, 18 (04): : 1318 - 1331
  • [23] Martínez F, 2017, PHARM SCI-IRAN, V23, P1, DOI 10.15171/PS.2017.01
  • [24] Mohammad Shafi MSh, 2015, INT J I PHARM LIFE S, V5, P330
  • [25] Negendra RJVV, 2017, INT J PHARMACEUT, V7, P94
  • [26] Rubino J.T., 1988, Encyclopedia of pharmaceutical technology, V3, P375, DOI DOI 10.1016/J.MOLLIQ.2015.12.005
  • [27] Solubilization of bosentan using ethanol as a pharmaceutical cosolvent
    Sajedi-Amin, Sanaz
    Barzegar-Jalali, Mohammad
    Fathi-Azarbayjani, Anahita
    Kebriaeezadeh, Abbas
    Martinez, Fleming
    Jouyban, Abolghasem
    [J]. JOURNAL OF MOLECULAR LIQUIDS, 2017, 232 : 152 - 158
  • [28] Salt formation to improve drug solubility
    Serajuddin, Abu T. M.
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) : 603 - 616
  • [29] Solubility and thermodynamic function of a bioactive compound bergenin in various pharmaceutically acceptable neat solvents at different temperatures
    Shakeel, Faiyaz
    AlAjmi, Mohamed F.
    Haq, Nazrul
    Siddiqui, Nasir A.
    Alam, Perwez
    Al-Rehaily, Adnan J.
    [J]. JOURNAL OF CHEMICAL THERMODYNAMICS, 2016, 101 : 19 - 24
  • [30] Tenjarla S, 1999, CRIT REV THER DRUG, V16, P461